Search - tctmd.com

Displaying 361 - 380 of 480

Sort: Relevancy | Date

Presentation TCT 2014

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Presenter: Matthew J. Price, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Presenter: Josep Rodés-Cabau, Mathew Williams, Azeem Latib

September 14, 2014

Presentation TCT 2014

Can LAA Closure Become the New Standard for Stroke Prevention?

Presenter: Hilary Nierenberg, Julie Logan, Saibal Kar

September 14, 2014

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation TCT 2014

The Electrophysiologists Approach to Managing Atrial Fibrillation

Presenter: Hilary Nierenberg, Julie Logan, Taya V. Glotzer

September 14, 2014

Presentation TCT 2014

Percutaneous Left Atrial Appendage Closure for Atrial Fibrillation: Where Are We Compared to New Drugs and Ablation

Presenter: Jose Luis Assad-Morell, Efrain Gaxiola, Matthew J. Price

September 13, 2014

Presentation TCT 2014

No: And Ill Show You Why!

Presenter: Sanjay Kaul, Ajay J. Kirtane, Joanna J. Wykrzykowska

September 13, 2014

Presentation TCT 2014

Yes: What is WORST is BEST!

Presenter: Sanjay Kaul, Ajay J. Kirtane, Christopher B. Granger

September 13, 2014

Presentation LAA 2014

Atrial Fibrillation and LAA Closure in a Patient Requiring PCI

Presenter: Matthew J. Price

July 19, 2014

Presentation LAA 2014

Atrial Fibrillation in Patient with Low Bleeding Risk

Presenter: John D. Carroll

July 19, 2014

Presentation LAA 2014

Quantifying stroke and bleeding risk in atrial fibrillation

Presenter: Stefan Bertog

July 17, 2014

Presentation

Cryptogenic Stroke and Underlying A-fib

Presenter: Tomasso Sanna

July 01, 2014

Presentation

A-fib in Patients with Cryptogenic Stroke or TIA

Presenter: D.J. Gladstone

July 01, 2014

Presentation

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Presenter: David R. Holmes Jr.

June 30, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

Presentation

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Presenter: Jonathan L. Halperin

June 09, 2014

Presentation EuroPCR 2014

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Presenter: Jos? Ram?n L?pez-M?nguez

May 21, 2014

Presentation

Importance of Persistent Elevation of Cardiac Biomarkers in A-Fib: RE-LY Substudy

Presenter: Z. Hijazi

May 09, 2014

Presentation

Anticoagulant and Antiplatelet Therapy in A-fib Patients Undergoing PCI

Presenter: K. Goto

April 30, 2014

Advertisement

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Can LAA Closure Become the New Standard for Stroke Prevention?

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

The Electrophysiologists Approach to Managing Atrial Fibrillation

Percutaneous Left Atrial Appendage Closure for Atrial Fibrillation: Where Are We Compared to New Drugs and Ablation

No: And Ill Show You Why!

Yes: What is WORST is BEST!

Atrial Fibrillation and LAA Closure in a Patient Requiring PCI

Atrial Fibrillation in Patient with Low Bleeding Risk

Quantifying stroke and bleeding risk in atrial fibrillation

Cryptogenic Stroke and Underlying A-fib

A-fib in Patients with Cryptogenic Stroke or TIA

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Importance of Persistent Elevation of Cardiac Biomarkers in A-Fib: RE-LY Substudy

Anticoagulant and Antiplatelet Therapy in A-fib Patients Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content